MedTrace Logo

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2010-01-15

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerablility of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of metformin.

Conditions

Interventions

DRUG

AZD1656

Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.

DRUG

Placebo

Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof., · AstraZeneca R&D Mölndal

  • Dr Emanuel DeNoia, MD · Healthcare Discoveries LLC Icon Development Solutions

  • Sanjay Sharma, MD · Veeda Clinical Research Pvt. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Completion
2010-01-31

Countries

  • United States
  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00774553 on ClinicalTrials.gov